Objective

The CRISPR technology is a powerful tool in target identification and target validation studies, because it can provide a mechanistic link between target function and disease biology. We will provide examples of how this technology can be used to select or validate new targets in the drug development pipeline though the generation of KO / KI in cell line systems. We will also present a system to robustly assess and optimise CRISPR/Cas9 delivery and efficiency to enable genome editing in primary cells. Finally this talk will conclude with the challenges that still exist and how new innovations in the field could help the acceleration of target selection studies